MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
27/10/2025 15:46
Oct 27 (Reuters) - Shares of MapLight Therapeutics MPLT.O opened 11.8% above their offer price in their Nasdaq debut on Monday, giving the drug developer a $787 million valuation. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shailesh Kuber) ((ArasuKannagi.Basil@thomsonreuters.com;))
Recent news on MapLight Therapeutics
See all newsUS and German scientists win Nobel medicine prize for work on light and brain (updated)
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
MapLight's schizophrenia drug fails once-daily test, shares plunge
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty